News
Press Releases
2022- ARS Pharmaceuticals Appoints Eric Karas as Chief Commercial Officer and Kathleen Scott as Chief Financial Officer
- ARS Pharmaceuticals Expands Executive Leadership Team with Addition of Pharmaceutical Commercialization Veterans
- ARS Pharmaceuticals, Inc. to Share New Data at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
- ARS Pharmaceuticals Raises $55 Million in Series D Funding for Launch Preparations of Neffy™ (epinephrine nasal spray)
- ARS Pharmaceuticals Strengthens Board of Directors with Appointment of Industry Leader and Innovator Brent Saunders
- ARS Announces Acceptance of Market Authorization Application submission to European Medicines Agency for Neffy™ (ARS-1; epinephrine nasal spray)
- ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for Neffy™ (ARS-1; epinephrine nasal spray)
- ARS Pharmaceuticals Announces New Patent on ARS-1 (epinephrine nasal spray)
- New Data from Neffy™ (ARS-1) Studies Profiled by AAAAI
- ARS Pharmaceuticals to present New Data from Neffy™ ARS-1) Studies at AAAAI 2020 Annual Meeting
- ARS Pharmaceuticals Announces the Appointment of Two New Board Members
- ARS Pharmaceuticals Announces Results from EPI-04 Clinical Study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis
- ARS Pharmaceuticals Announces FDA Fast Track Designation for ARS-1 Intranasal Epinephrine Spray